Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma . mfm. 2024;35(6). Accessed February 1, 2026. https://medicalforummonthly.com/index.php/mfm/article/view/4698